AbbVie Pharmaceuticals

September 17, 2015September 17, 2015

Long-Term Follow-Up Study Confirms Ibrutinib Effective in Relapsed/Refractory Mantle Cell Lymphoma

News

According to a new report that appeared August 6th in the journal Blood, ibrutinib sustains benefits in people with relapsed or refractory mantle cell lymphoma. The 26.7 month follow-up of a Phase 2 trial of ... Read more

September 7, 2015September 9, 2015

FDA Accepts Bristol-Myers Squibb’s and AbbVie’s Empliciti for Multiple Myeloma BLA for Priority Review

News

The US Food and Drug Administration has accepted Bristol-Myers Squibb Company’s and AbbVie’s joint Biologics License Application (BLA) for Empliciti’s (elotuzumab) priority review. Empliciti is an experimental Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody, for the ... Read more

September 1, 2015September 1, 2015

Phase II Study of Investigational Medicine Venetoclax Meets Primary Endpoint With Positive Results

News

Genentech in partnership with AbbVie Pharmaceuticals and the Leukemia & Lymphoma Society (LLS), recently announced positive results from a Phase 1 clinical trial for venetoclax, an investigational therapy to treat patients with ... Read more